{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:06:09Z","timestamp":1789718769695,"version":"4.0.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Gujarat State Biotechnology Mission, Government of Gujarat, India.","award":["GSBTM\/MD\/PROJECTS\/SSA\/4887\/2016-17"],"award-info":[{"award-number":["GSBTM\/MD\/PROJECTS\/SSA\/4887\/2016-17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05652-4","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:48:38Z","timestamp":1768207718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Valacyclovir Mitigates Amyloid Plaque Deposition, P-Tau Aggregation, and Neuroinflammation in Streptozotocin induced Alzheimer's Disease Rat Model"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7910-9473","authenticated-orcid":false,"given":"Parmi","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigna","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"5652_CR1","unstructured":"ADI - Dementia statistics (n.d.) URL https:\/\/www.alzint.org\/about\/dementia-facts-figures\/dementia-statistics\/ (accessed 11.6.25)"},{"key":"5652_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41582-024-00940-4","volume":"20","author":"AD Korczyn","year":"2024","unstructured":"Korczyn AD, Grinberg LT (2024) Is alzheimer disease a disease? Nat Rev Neurol 20:245\u2013251. https:\/\/doi.org\/10.1038\/s41582-024-00940-4","journal-title":"Nat Rev Neurol"},{"key":"5652_CR3","doi-asserted-by":"publisher","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"5652_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8:595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210","journal-title":"EMBO Mol Med"},{"key":"5652_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256:184\u2013185. https:\/\/doi.org\/10.1126\/science.1566067","journal-title":"Science"},{"key":"5652_CR6","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/JCI10498","volume":"106","author":"M Shibata","year":"2000","unstructured":"Shibata M, Yamada S, Kumar S et al (2000) Clearance of Alzheimer\u2019s amyloid-\u03b21-40 peptide from brain by LDL receptor\u2013related protein-1 at the blood-brain barrier. J Clin Invest 106:1489\u20131499. https:\/\/doi.org\/10.1172\/JCI10498","journal-title":"J Clin Invest"},{"key":"5652_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4062\/biomolther.2012.20.3.2451","volume":"20","author":"S-S Yoon","year":"2012","unstructured":"Yoon S-S, Jo SA (2012) Mechanisms of amyloid-\u03b2 peptide clearance: potential therapeutic targets for Alzheimer\u2019s disease. Biomol Ther (Seoul) 20:245\u2013255. https:\/\/doi.org\/10.4062\/biomolther.2012.20.3.2451","journal-title":"Biomol Ther (Seoul)"},{"key":"5652_CR8","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.tim.2020.03.003","volume":"28","author":"ME Marcocci","year":"2020","unstructured":"Marcocci ME, Napoletani G, Protto V et al (2020) Herpes simplex virus-1 in the brain: the dark side of a sneaky infection. Trends Microbiol 28:808\u2013820. https:\/\/doi.org\/10.1016\/j.tim.2020.03.003","journal-title":"Trends Microbiol"},{"key":"5652_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007617","volume":"15","author":"G De Chiara","year":"2019","unstructured":"De Chiara G, Piacentini R, Fabiani M et al (2019) Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS Pathog 15:e1007617. https:\/\/doi.org\/10.1371\/journal.ppat.1007617","journal-title":"PLoS Pathog"},{"key":"5652_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/jmv.1890330403","volume":"33","author":"GA Jamieson","year":"1991","unstructured":"Jamieson GA, Maitland NJ, Wilcock GK et al (1991) Latent herpes simplex virus type 1 in normal and Alzheimer\u2019s disease brains. J Med Virol 33:224\u2013227. https:\/\/doi.org\/10.1002\/jmv.1890330403","journal-title":"J Med Virol"},{"key":"5652_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.1711670403","volume":"167","author":"GA Jamieson","year":"1992","unstructured":"Jamieson GA, Maitland NJ, Wilcock GK et al (1992) Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. J Pathol 167:365\u2013368. https:\/\/doi.org\/10.1002\/path.1711670403","journal-title":"J Pathol"},{"key":"5652_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03166-9","volume":"21","author":"Z Wang","year":"2024","unstructured":"Wang Z, Liu J, Han J et al (2024) Herpes simplex virus 1 accelerates the progression of Alzheimer\u2019s disease by modulating microglial phagocytosis and activating NLRP3 pathway. J Neuroinflammation 21:176. https:\/\/doi.org\/10.1186\/s12974-024-03166-9","journal-title":"J Neuroinflammation"},{"key":"5652_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.neulet.2007.09.077","volume":"429","author":"MA Wozniak","year":"2007","unstructured":"Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB (2007) Herpes simplex virus infection causes cellular \u03b2-amyloid accumulation and secretase upregulation. Neurosci Lett 429:95\u2013100. https:\/\/doi.org\/10.1016\/j.neulet.2007.09.077","journal-title":"Neurosci Lett"},{"key":"5652_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3233\/JAD-2009-09631","volume":"16","author":"MA Wozniak","year":"2009","unstructured":"Wozniak MA, Frost AL, Itzhaki RF (2009) Alzheimer\u2019s disease-specific tau phosphorylation is induced by herpes simplex virus type 1. JAD 16:341\u2013350. https:\/\/doi.org\/10.3233\/JAD-2009-09631","journal-title":"JAD"},{"key":"5652_CR15","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/jnr.23003","volume":"90","author":"G \u00c1lvarez","year":"2012","unstructured":"\u00c1lvarez G, Aldudo J, Alonso M et al (2012) Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. J Neurosci Res 90:1020\u20131029. https:\/\/doi.org\/10.1002\/jnr.23003","journal-title":"J Neurosci Res"},{"key":"5652_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3233\/JAD-2008-143011","volume":"14","author":"\u00c1 Zambrano","year":"2008","unstructured":"Zambrano \u00c1, Solis L, Salvadores N et al (2008) Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with Herpes simplex virus type 1. JAD 14:259\u2013269. https:\/\/doi.org\/10.3233\/JAD-2008-143011","journal-title":"JAD"},{"key":"5652_CR17","doi-asserted-by":"crossref","unstructured":"De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV (2012) Alzheimer\u2019s Disease. In: Harris JR (ed) Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease. Springer Netherlands, Dordrecht, pp 329\u2013352 1","DOI":"10.1007\/978-94-007-5416-4_14"},{"key":"5652_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jocn.2020.10.044","volume":"82","author":"D Wu","year":"2020","unstructured":"Wu D, Wang C, Pang P et al (2020) The association between herpes simplex virus type 1 infection and Alzheimer\u2019s disease. J Clin Neurosci 82:63\u201370. https:\/\/doi.org\/10.1016\/j.jocn.2020.10.044","journal-title":"J Clin Neurosci"},{"key":"5652_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/106002809703100211","volume":"31","author":"EP Acosta","year":"1997","unstructured":"Acosta EP, Fletcher CV (1997) Valacyclovir. Ann Pharmacother 31:185\u2013191. https:\/\/doi.org\/10.1177\/106002809703100211","journal-title":"Ann Pharmacother"},{"key":"5652_CR20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1128\/aac.00729-09","volume":"54","author":"JP Smith","year":"2010","unstructured":"Smith JP, Weller S, Johnson B et al (2010) Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother 54:1146\u20131151. https:\/\/doi.org\/10.1128\/aac.00729-09","journal-title":"Antimicrob Agents Chemother"},{"key":"5652_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1191\/1352458505ms1185oa","volume":"11","author":"JE Friedman","year":"2005","unstructured":"Friedman JE, Zabriskie JB, Plank C et al (2005) A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler 11:286\u2013295. https:\/\/doi.org\/10.1191\/1352458505ms1185oa","journal-title":"Mult Scler"},{"key":"5652_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2004.05.010","volume":"189","author":"H-M Wu","year":"2004","unstructured":"Wu H-M, Liang Y-C, Chen S-H et al (2004) Valacyclovir treatment ameliorates the persistently increased pentylenetetrazol-induced seizure susceptibility in mice with herpes simplex virus type 1 infection. Exp Neurol 189:66\u201377. https:\/\/doi.org\/10.1016\/j.expneurol.2004.05.010","journal-title":"Exp Neurol"},{"key":"5652_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/schbul\/sbs040","volume":"39","author":"KM Prasad","year":"2013","unstructured":"Prasad KM, Eack SM, Keshavan MS et al (2013) Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial. Schizophr Bull 39:857\u2013866. https:\/\/doi.org\/10.1093\/schbul\/sbs040","journal-title":"Schizophr Bull"},{"key":"5652_CR24","doi-asserted-by":"publisher","first-page":"e032112","DOI":"10.1136\/bmjopen-2019-0321121","volume":"10","author":"DP Devanand","year":"2020","unstructured":"Devanand DP, Andrews H, Kreisl WC et al (2020) Antiviral therapy: Valacyclovir treatment of Alzheimer\u2019s Disease (VALAD) trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial. BMJ Open 10:e032112. https:\/\/doi.org\/10.1136\/bmjopen-2019-0321121","journal-title":"BMJ Open"},{"key":"5652_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1037\/0735-7044.112.5.1199","volume":"112","author":"H Lannert","year":"1998","unstructured":"Lannert H, Hoyer S (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112:1199\u20131208. https:\/\/doi.org\/10.1037\/0735-7044.112.5.1199","journal-title":"Behav Neurosci"},{"key":"5652_CR26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2174\/1567205011310040006","volume":"10","author":"SC Correia","year":"2013","unstructured":"Correia SC, Santos RX, Santos MS et al (2013) Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer\u2019s disease. Curr Alzheimer Res 10:406\u2013419. https:\/\/doi.org\/10.2174\/1567205011310040006","journal-title":"Curr Alzheimer Res"},{"key":"5652_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JAD-2012-120958","volume":"33","author":"J Mehla","year":"2013","unstructured":"Mehla J, Pahuja M, Gupta YK (2013) Streptozotocin-induced sporadic Alzheimer\u2019s disease: selection of appropriate dose. J Alzheimers Dis 33:17\u201321. https:\/\/doi.org\/10.3233\/JAD-2012-120958","journal-title":"J Alzheimers Dis"},{"key":"5652_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0272-0590(83)80107-91","volume":"3","author":"WE Tucker","year":"1983","unstructured":"Tucker WE, Macklin AW, Szot RJ et al (1983) Preclinical toxicology studies with acyclovir: Acute and subchronic tests. Fundam Appl Toxicol 3:573\u2013578. https:\/\/doi.org\/10.1016\/S0272-0590(83)80107-91","journal-title":"Fundam Appl Toxicol"},{"key":"5652_CR29","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.biopha.2018.03.115","volume":"102","author":"P Barai","year":"2018","unstructured":"Barai P, Raval N, Acharya S, Acharya N (2018) Bergenia ciliata ameliorates streptozotocin-induced spatial memory deficits through dual cholinesterase inhibition and attenuation of oxidative stress in rats. Biomed Pharmacother 102:966\u2013980. https:\/\/doi.org\/10.1016\/j.biopha.2018.03.115","journal-title":"Biomed Pharmacother"},{"key":"5652_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbr.2018.08.010","volume":"356","author":"P Barai","year":"2019","unstructured":"Barai P, Raval N, Acharya S et al (2019) Neuroprotective effects of bergenin in Alzheimer\u2019s disease: investigation through molecular docking, in vitro and in vivo studies. Behav Brain Res 356:18\u201340. https:\/\/doi.org\/10.1016\/j.bbr.2018.08.010","journal-title":"Behav Brain Res"},{"issue":"2","key":"5652_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0023-9690(81)90020-5","volume":"12","author":"RGM Morris","year":"1981","unstructured":"Morris RGM (1981) Spatial localization does not require the presence of local cues. Learn Motiv 12(2):239\u2013260. https:\/\/doi.org\/10.1016\/0023-9690(81)90020-5","journal-title":"Learn Motiv"},{"key":"5652_CR32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/nprot.2006.116","volume":"1","author":"CV Vorhees","year":"2006","unstructured":"Vorhees CV, Williams MT (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1:848\u2013858. https:\/\/doi.org\/10.1038\/nprot.2006.116","journal-title":"Nat Protoc"},{"key":"5652_CR33","doi-asserted-by":"publisher","unstructured":"Bromley-Brits K, Deng Y, Song W (2011) Morris water maze test for learning and memory deficits in Alzheimer\u2019s Disease model mice. JoVE 2920. https:\/\/doi.org\/10.3791\/2920","DOI":"10.3791\/2920"},{"key":"5652_CR34","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1007\/s00213-021-05942-4","volume":"238","author":"N Bruszt","year":"2021","unstructured":"Bruszt N, Bali ZK, Tadepalli SA et al (2021) Potentiation of cognitive enhancer effects of Alzheimer\u2019s disease medication memantine by alpha7 nicotinic acetylcholine receptor agonist PHA-543613 in the Morris water maze task. Psychopharmacology 238:3273\u20133281. https:\/\/doi.org\/10.1007\/s00213-021-05942-4","journal-title":"Psychopharmacology"},{"issue":"1","key":"5652_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0006-8993(97)00236-9","volume":"759","author":"CD Conrad","year":"1997","unstructured":"Conrad CD, Lupien SJ, Thanasoulis LC, McEwen BS (1997) The effects of type I and type II corticosteroid receptor agonists on exploratory behavior and spatial memory in the Y-maze. Brain Res 759(1):76\u201383. https:\/\/doi.org\/10.1016\/S0006-8993(97)00236-9","journal-title":"Brain Res"},{"issue":"1","key":"5652_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02182-3","volume":"18","author":"X Sun","year":"2021","unstructured":"Sun X, Li L, Dong Q-X et al (2021) Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer\u2019s disease. J Neuroinflammation 18(1):131. https:\/\/doi.org\/10.1186\/s12974-021-02182-3","journal-title":"J Neuroinflammation"},{"key":"5652_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137062","volume":"22","author":"LC Camargo","year":"2021","unstructured":"Camargo LC, Sch\u00f6neck M, Sangarapillai N et al (2021) PEA\u03b2 triggers cognitive decline and amyloid burden in a novel mouse model of Alzheimer\u2019s disease. Int J Mol Sci 22:7062. https:\/\/doi.org\/10.3390\/ijms22137062","journal-title":"Int J Mol Sci"},{"issue":"265\u2013275","key":"5652_CR38","first-page":"1","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(265\u2013275):1","journal-title":"J Biol Chem"},{"key":"5652_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","volume":"7","author":"GL Ellman","year":"1961","unstructured":"Ellman GL, Courtney KD, Andres V, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88\u201395. https:\/\/doi.org\/10.1016\/0006-2952(61)90145-9","journal-title":"Biochem Pharmacol"},{"key":"5652_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","volume":"95","author":"H Ohkawa","year":"1979","unstructured":"Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351\u2013358. https:\/\/doi.org\/10.1016\/0003-2697(79)90738-3","journal-title":"Anal Biochem"},{"key":"5652_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000136485","volume":"11","author":"DJ Jollow","year":"1974","unstructured":"Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR (1974) Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 11:151\u2013169. https:\/\/doi.org\/10.1159\/000136485","journal-title":"Pharmacology"},{"issue":"1","key":"5652_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0003-2697(78)90010-6","volume":"90","author":"M Sun","year":"1978","unstructured":"Sun M, Zigman S (1978) An improved spectrophotometric assay for superoxide dismutase based on epinephrine autoxidation. Anal Biochem 90(1):81\u201389. https:\/\/doi.org\/10.1016\/0003-2697(78)90010-6","journal-title":"Anal Biochem"},{"key":"5652_CR43","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/aps.2013.203","volume":"35","author":"L-L Zhang","year":"2014","unstructured":"Zhang L-L, Sui H-J, Liang B et al (2014) Atorvastatin prevents amyloid-\u03b2 peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway. Acta Pharmacol Sin 35:716\u2013726. https:\/\/doi.org\/10.1038\/aps.2013.203","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"5652_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0524-y","volume":"26","author":"MVF Silva","year":"2019","unstructured":"Silva MVF, Loures CdeMG, Alves LCV et al (2019) Alzheimer\u2019s disease: risk factors and potentially protective measures. J Biomed Sci 26(1):33. https:\/\/doi.org\/10.1186\/s12929-019-0524-y","journal-title":"J Biomed Sci"},{"key":"5652_CR45","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4103\/1673-5374.3209701","volume":"17","author":"Y Ju","year":"2021","unstructured":"Ju Y, Tam KY (2021) Pathological mechanisms and therapeutic strategies for Alzheimer\u2019s disease. Neural Regen Res 17:543\u2013549. https:\/\/doi.org\/10.4103\/1673-5374.3209701","journal-title":"Neural Regen Res"},{"key":"5652_CR46","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.neuroscience.2016.01.041","volume":"322","author":"Y-X Guo","year":"2016","unstructured":"Guo Y-X, He L-Y, Zhang M et al (2016) 1,25-dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing A\u03b21\u201340 brain-to-blood efflux and peripheral uptake transport. Neuroscience 322:28\u201338. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.01.041","journal-title":"Neuroscience"},{"key":"5652_CR47","doi-asserted-by":"publisher","unstructured":"Grimm MO, Mett J, Stahlmann CP, et al (2013) Neprilysin and A\u03b2 clearance: Impact of the APP intracellular domain in NEP regulation and implications in Alzheimer\u2019s Disease. Front Aging Neurosci 5:. https:\/\/doi.org\/10.3389\/fnagi.2013.00098 1","DOI":"10.3389\/fnagi.2013.00098"},{"key":"5652_CR48","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1111\/febs.16939","volume":"291","author":"J \u017bukowska","year":"2024","unstructured":"\u017bukowska J, Moss SJ, Subramanian V, Acharya KR (2024) Molecular basis of selective amyloid-\u03b2 degrading enzymes in Alzheimer\u2019s disease. FEBS J 291:2999\u20133029. https:\/\/doi.org\/10.1111\/febs.16939","journal-title":"FEBS J"},{"key":"5652_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2016.00160","author":"M Ries","year":"2016","unstructured":"Ries M, Sastre M (2016) Mechanisms of A\u03b2 clearance and degradation by glial cells. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2016.00160","journal-title":"Front Aging Neurosci"},{"key":"5652_CR50","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1073\/pnas.0230450100","volume":"100","author":"W Farris","year":"2003","unstructured":"Farris W, Mansourian S, Chang Y et al (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid \u03b2-protein, and the \u03b2-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100:4162\u20134167. https:\/\/doi.org\/10.1073\/pnas.0230450100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5652_CR51","doi-asserted-by":"publisher","first-page":"718","DOI":"10.14283\/jpad.2023.114","volume":"10","author":"M Barbera","year":"2023","unstructured":"Barbera M, Perera D, Matton A et al (2023) Multimodal precision prevention - a new direction in Alzheimer\u2019s disease. J Prev Alzheimers Dis 10:718\u2013728. https:\/\/doi.org\/10.14283\/jpad.2023.114","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"5652_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-med-051022-043645","volume":"75","author":"JL Heidebrink","year":"2024","unstructured":"Heidebrink JL, Paulson HL (2024) Lessons learned from approval of Aducanumab for Alzheimer\u2019s disease. Annu Rev Med 75(1):99\u2013111. https:\/\/doi.org\/10.1146\/annurev-med-051022-043645","journal-title":"Annu Rev Med"},{"key":"5652_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13311-018-0611-x","volume":"15","author":"N-S Tzeng","year":"2018","unstructured":"Tzeng N-S, Chung C-H, Lin F-H et al (2018) Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections-a nationwide, population-based cohort study in Taiwan. Neurotherapeutics 15:417\u2013429. https:\/\/doi.org\/10.1007\/s13311-018-0611-x","journal-title":"Neurotherapeutics"},{"key":"5652_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060679","volume":"9","author":"RF Itzhaki","year":"2021","unstructured":"Itzhaki RF (2021) Overwhelming evidence for a major role for Herpes simplex virus type 1 (HSV1) in Alzheimer\u2019s disease (AD); underwhelming evidence against. Vaccines 9:679. https:\/\/doi.org\/10.3390\/vaccines9060679","journal-title":"Vaccines"},{"key":"5652_CR55","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/jnnp.47.10.1061","volume":"47","author":"GR Taylor","year":"1984","unstructured":"Taylor GR, Crow TJ, Markakis DA et al (1984) Herpes simplex virus and Alzheimer\u2019s disease: a search for virus DNA by spot hybridisation. J Neurol Neurosurg Psychiatry 47:1061\u20131065. https:\/\/doi.org\/10.1136\/jnnp.47.10.1061","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5652_CR56","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jalz.2008.12.0011","volume":"5","author":"K Honjo","year":"2009","unstructured":"Honjo K, van Reekum R, Verhoeff NPLG (2009) Alzheimer\u2019s disease and infection: do infectious agents contribute to progression of Alzheimer\u2019s disease? Alzheimers Dement 5:348\u2013360. https:\/\/doi.org\/10.1016\/j.jalz.2008.12.0011","journal-title":"Alzheimers Dement"},{"key":"5652_CR57","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/s0140-6736(79)91667-2","volume":"2","author":"LW Sequiera","year":"1979","unstructured":"Sequiera LW, Jennings LC, Carrasco LH et al (1979) Detection of herpes-simplex viral genome in brain tissue. Lancet 2:609\u2013612. https:\/\/doi.org\/10.1016\/s0140-6736(79)91667-2","journal-title":"Lancet"},{"key":"5652_CR58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1006\/mcpr.2001.0356","volume":"15","author":"JB Peter","year":"2001","unstructured":"Peter JB, Sevall JS (2001) Review of 3200 serially received CSF samples submitted for type-specific HSV detection by PCR in the reference laboratory setting. Mol Cell Probes 15:177\u2013182. https:\/\/doi.org\/10.1006\/mcpr.2001.0356","journal-title":"Mol Cell Probes"},{"key":"5652_CR59","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.jalz.2018.06.3040","volume":"14","author":"RD Moir","year":"2018","unstructured":"Moir RD, Lathe R, Tanzi RE (2018) The antimicrobial protection hypothesis of Alzheimer\u2019s disease. Alzheimers Dement 14:1602\u20131614. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.3040","journal-title":"Alzheimers Dement"},{"key":"5652_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.695738","author":"SJ Yong","year":"2021","unstructured":"Yong SJ, Yong MH, Teoh SL et al (2021) The hippocampal vulnerability to Herpes simplex virus type I infection: relevance to Alzheimer\u2019s disease and memory impairment. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2021.695738","journal-title":"Front Cell Neurosci"},{"key":"5652_CR61","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.antiviral.2013.07.003","volume":"99","author":"MA Wozniak","year":"2013","unstructured":"Wozniak MA, Frost AL, Itzhaki RF (2013) The helicase-primase inhibitor BAY 57\u20131293 reduces the Alzheimer\u2019s disease-related molecules induced by herpes simplex virus type 1. Antivir Res 99:401\u2013404. https:\/\/doi.org\/10.1016\/j.antiviral.2013.07.003","journal-title":"Antivir Res"},{"key":"5652_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025152","volume":"6","author":"MA Wozniak","year":"2011","unstructured":"Wozniak MA, Frost AL, Preston CM, Itzhaki RF (2011) Antivirals reduce the formation of key Alzheimer\u2019s disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS One 6:e25152. https:\/\/doi.org\/10.1371\/journal.pone.0025152","journal-title":"PLoS One"},{"key":"5652_CR63","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/sti.2004.012039","volume":"81","author":"KJ Looker","year":"2005","unstructured":"Looker KJ (2005) A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect 81:103\u2013107. https:\/\/doi.org\/10.1136\/sti.2004.012039","journal-title":"Sex Transm Infect"},{"issue":"1","key":"5652_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12264","volume":"8","author":"B Weidung","year":"2022","unstructured":"Weidung B, Hemmingsson E-S, Olsson J et al (2022) VALZ-pilot: High-dose valacyclovir treatment in patients with early-stage Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions 8(1):e12264. https:\/\/doi.org\/10.1002\/trc2.12264","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"5652_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2022.148175","volume":"1799","author":"SSL Silva","year":"2023","unstructured":"Silva SSL, Tureck LV, Souza LC et al (2023) Animal model of Alzheimer\u2019s disease induced by streptozotocin: new insights about cholinergic pathway. Brain Res 1799:148175. https:\/\/doi.org\/10.1016\/j.brainres.2022.148175","journal-title":"Brain Res"},{"key":"5652_CR66","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/jnc.15155","volume":"158","author":"T Yuliani","year":"2021","unstructured":"Yuliani T, Lobentanzer S, Klein J (2021) Central cholinergic function and metabolic changes in streptozotocin-induced rat brain injury. J Neurochem 158:1307\u20131319. https:\/\/doi.org\/10.1111\/jnc.15155","journal-title":"J Neurochem"},{"key":"5652_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113375","volume":"153","author":"M Fan","year":"2022","unstructured":"Fan M, Liu S, Sun H-M et al (2022) Bilateral intracerebroventricular injection of streptozotocin induces AD-like behavioral impairments and neuropathological features in mice: involved with the fundamental role of neuroinflammation. Biomed Pharmacother 153:113375. https:\/\/doi.org\/10.1016\/j.biopha.2022.113375","journal-title":"Biomed Pharmacother"},{"key":"5652_CR68","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.3397","volume":"9","author":"D Moreira-Silva","year":"2019","unstructured":"Moreira-Silva D, Vizin RCL, Martins TMS et al (2019) Intracerebral injection of streptozotocin to model Alzheimer disease in rats. BIO-PROTOCOL 9:e3397. https:\/\/doi.org\/10.21769\/BioProtoc.3397","journal-title":"BIO-PROTOCOL"},{"key":"5652_CR69","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s00213-020-05503-1","volume":"237","author":"Z Hui","year":"2020","unstructured":"Hui Z, Zhijun Y, Yushan Y et al (2020) The combination of acyclovir and dexamethasone protects against Alzheimer\u2019s disease-related cognitive impairments in mice. Psychopharmacology 237:1851\u20131860. https:\/\/doi.org\/10.1007\/s00213-020-05503-1","journal-title":"Psychopharmacology"},{"key":"5652_CR70","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2174\/1567202619666220908125125","volume":"19","author":"P Patel","year":"2022","unstructured":"Patel P, Faldu K, Borisa A, Bhatt H, Shah J (2022) Insights of valacyclovir in treatment of Alzheimer\u2019s disease: computational docking studies and scopolamine rat model. Curr Neurovasc Res 19:344\u2013357. https:\/\/doi.org\/10.2174\/1567202619666220908125125","journal-title":"Curr Neurovasc Res"},{"key":"5652_CR71","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1096\/fj.2017003601","volume":"31","author":"RF Itzhaki","year":"2017","unstructured":"Itzhaki RF (2017) Herpes simplex virus type 1 and Alzheimer\u2019s disease: possible mechanisms and signposts.","journal-title":"FASEB J"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05652-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05652-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05652-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:42:50Z","timestamp":1768473770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05652-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5652"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05652-4","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"356"}}